8-K: Sotera Health Exceeds $1.16B Revenue in 2025

Sotera Health Company announced preliminary full-year 2025 revenue exceeding $1.16 billion, marking over two decades of continuous growth.

Summary

• Preliminary revenue for full-year 2025 is expected to surpass $1.16 billion.
• This represents an increase of at least 5.5% year over year, or 5.0% on a constant-currency basis.
• The company has achieved over two decades of year-over-year revenue growth.
• Preliminary revenue results are within the guidance provided at the time of the third quarter earnings release.
• Management will deliver a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at approximately 1:30 p.m. Eastern Time.
• Full-year results and the 2026 outlook are expected to be shared on February 24, 2026.

Sentiment

Score: 7

Explanation: The preliminary financial results are positive, showing consistent growth and meeting prior guidance, which indicates a stable and durable business model. However, these are preliminary figures, and a comprehensive list of risks is provided, warranting a balanced view.

Positives

• Preliminary full-year 2025 revenue is expected to surpass $1.16 billion.
• Achieved at least 5.5% year-over-year revenue growth (5.0% on a constant-currency basis).
• Marks over two decades of continuous year-over-year revenue growth, demonstrating business model durability.
• Preliminary revenue results are consistent with prior guidance, indicating predictable performance.

Risks

• Disruption in the availability or supply of, or increases in the price of, EO, Co-60, or other direct materials, services, and supplies, including due to geopolitical instability and/or sanctions against Russia.
• Fluctuations in foreign currency exchange rates.
• Evolving changes in environmental, health, and safety regulations or preferences, and general economic, social, and business conditions.
• Health and safety risks associated with the use, storage, transportation, and disposal of potentially hazardous materials such as EO and Co-60.
• Impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions, and releases of EO from facilities in California, Georgia, Illinois, and New Mexico, and the possibility of additional claims.
• Ability to satisfy the conditions for settlement of the EO claims related to the former facility in Willowbrook, Illinois.
• Allegations of failure to properly perform services and potential product liability claims, recalls, penalties, and reputational harm.
• Compliance with extensive regulatory requirements, related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals.
• Adverse changes in industry trends and competition.
• Market conditions and changes, including inflationary trends and the impact of tariffs, that affect long-term supply contracts with variable price clauses and increase cost of revenues.
• Business continuity hazards, including supply chain disruptions, the impact of the U.S. federal government shutdown, and other operational risks.
• Risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable laws and potentially inconsistent laws and regulations in multiple jurisdictions.
• Ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner, and renew leases for leased facilities.
• Ability to attract and retain qualified employees.
• Severe health events or environmental events.
• Cybersecurity incidents, unauthorized data disclosures, and dependence on information technology systems.
• Inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions successfully.
• Ability to maintain effective internal control over financial reporting.
• Reliance on intellectual property to maintain competitive position and the risk of claims from third parties regarding infringement or misappropriation.
• Ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts.
• Ability to generate profitability in future periods.
• Impairment charges on goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives.
• Effects of unionization efforts and labor regulations in countries of operation.
• Adverse changes to tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of operations.
• Significant leverage and how this could adversely affect the ability to raise additional capital, limit ability to react to challenges, limit flexibility in operating the business through debt agreement restrictions, and/or prevent meeting obligations under existing and future agreements governing indebtedness.

Future Outlook

Management will provide a comprehensive 2026 outlook along with the full-year 2025 results on February 24, 2026. The preliminary 2025 revenue results are consistent with previously issued guidance.

Management Comments

• "Sotera Health continued its solid growth trajectory in 2025, with revenue expected to surpass $1.16 billion, an increase of at least 5.5% year over year, or 5.0% on a constant-currency basis."
• "This marks over two decades of year-over-year revenue growth, reflecting the durability of our business model, the strength and consistency of our financial profile, and our continued commitment to serve our customers with excellence."
• "We look forward to sharing our full-year results and 2026 outlook on February 24, 2026."

Industry Context

Sotera Health operates as a leading global provider of mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry. This sector is essential for medical device and pharmaceutical manufacturing, implying a stable demand for its services. The consistent revenue growth over two decades suggests the company maintains a strong competitive position and resilience within this vital industry.

Legal Proceedings

• Current and future legal proceedings and liability claims, including litigation related to the use, emissions, and releases of EO from facilities in California, Georgia, Illinois, and New Mexico.
• The possibility that additional claims will be made in the future relating to these or other facilities.
• Ability to satisfy the conditions for settlement of the EO claims related to the former facility in Willowbrook, Illinois.

Stakeholder Impact

• Shareholders: Positive preliminary revenue results and consistent growth could instill confidence, but full audited results and 2026 outlook on February 24, 2026, will be key for further evaluation.
• Customers: The company's commitment to serving customers with excellence suggests continued reliable service provision for mission-critical healthcare solutions.
• Employees: The ability to attract and retain qualified employees is noted as a risk, highlighting its importance for operational continuity.
• Creditors: The company's significant leverage is identified as a risk, potentially impacting its ability to raise additional capital or meet debt obligations.

Next Steps

• Management will deliver a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
• Release full-year results and 2026 outlook on February 24, 2026.

Key Dates

Recommendation

The preliminary revenue results are positive, showing consistent growth and meeting prior guidance, which indicates a stable and durable business model in a critical healthcare sector. However, these are preliminary figures, and the full financial picture and 2026 outlook are yet to be released on February 24, 2026. The extensive list of risks, particularly those related to EO litigation and significant leverage, warrants a cautious approach. Investors should hold pending the release of audited full-year results and detailed 2026 guidance to assess the company's complete financial health and future prospects.

Keywords

Sotera Health, SHC, Sterigenics, Nordion, Nelson Labs, sterilization solutions, lab testing, healthcare industry, financial results, revenue growth, J.P. Morgan Healthcare Conference, SEC filing, 8-K